MASON, OH; November 6, 2013 — Aprecia Pharmaceuticals Company (“Aprecia” or “the company”) announced today that it has selected Don Wetherhold to serve as the company’s next chief executive officer. Wetherhold previously served as senior vice president, long-term care at Omnicare, Inc. Prior to his time at Omnicare, Wetherhold was Aprecia’s corporate commercialization officer.
“We are thrilled to have Don back at Aprecia, and we look forward to the leadership he will bring to this role,” said E. Thomas Arington, Aprecia’s chairman. “Don was instrumental in devising our commercialization strategy at Aprecia. We are now preparing to file our first product, and we have two additional products in development. The company is poised for commercial success, and Don’s expertise and commitment certainly augment Aprecia’s momentum.
“We also know that Don’s extensive experience within the healthcare field will serve both him and the company well. Furthermore, we highly value not only his experience and intelligence but also his character,” Arington concluded.
“I’m excited to be back at Aprecia for a number of reasons, not the least of which is the rare opportunity to be the first at something and redefine a market—which is what our breakthrough 3DP product development and manufacturing system has the potential to do,” stated Wetherhold. “Aprecia’s technology is being used to enhance the delivery of gold-standard pharmaceutical products, thereby improving treatment adherence for certain patient populations. The company’s vision is to make medicines easier to take, and Aprecia has made great strides toward that vision this past year.”
Wetherhold has 26 years of experience in the healthcare industry, including key management positions and leadership roles at Omnicare, Cardinal Health, Snyder Healthcare Sales, and Solvay Pharmaceuticals. Prior to his first tenure with Aprecia in 2010, he served as Prasco Laboratories’ senior vice president and general manager of Hampton Laine, Prasco’s branded pharmaceutical business.
Aprecia is a unique specialty pharmaceutical company built upon an innovative 3DP (three-dimensional printing) technology and manufacturing system. Aprecia is the first and only company in the world to utilize this technology to develop and manufacture pharmaceutical products at commercial scale.